A Single Ascending Dose Study for the Evaluation of the Effects of LY3039478 on the QT/Corrected QT Interval in Healthy Subjects and Pilot Relative Bioavailability

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Crenigacestat (Primary)
Indications Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
Focus Adverse reactions
Sponsors Eli Lilly and Company

30 Oct 2017 Results from this and 2 otehr studies, presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
25 Oct 2017 Outcomes of population PK/PD model developed using data from first human dose trial (NCT01695005,n=102) and single ascending dose and pilot relative bioavailability study (NCT02659865,n=34),presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017.
11 Jul 2016 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com